Skip to contentDEEKOYA AI CoursesFLAT 20% OFFEnroll Now
Deekoya AI

Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted

Unite.AI ·

generalnews

Summary

Harbour BioMed announced on November 18, 2026 that China’s National Medical Products Administration had accepted the investigational new drug (IND) application for LET003, its first drug candidate developed using the Hu-mAtrIx AI platform. The monoclonal antibody is intended to t

Source
Unite.AI
Published (IST)
Read the full story on Unite.AI

Original reporting belongs to Unite.AI. DEEKOYA links the headline and a short excerpt only; we do not republish the full article.

Explore more: Today in AI · Research papers · AI tools · Learn AI

Related stories

Who reported “Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted”?

Unite.AI, on 19 Nov 2026. The full article is at the source link on this page.

Comments

No comments yet. Share your own experience below.

Visitor posts are moderated before they appear and are the opinion of their authors, not DEEKOYA AI. Names are not verified. See our privacy policy.